Quince Therapeutics, Inc. Current Liabilities
Quince Therapeutics, Inc. (QNCX) had Current Liabilities of $8.50 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-14
- 2026-06-30: Liabilities, Current $8.50M.
- 2026-03-31: Liabilities, Current $8.77M.
- 2025-12-31: Liabilities, Current $43.23M.
- 2025-09-30: Liabilities, Current $26.04M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $8.50M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $8.77M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $43.23M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $26.04M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $7.47M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $8.36M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $7.28M 10-K · filed 2026-04-10 |
| 2024-09-30 | $5.42M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $10.32M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $9.84M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $9.57M 10-K · filed 2025-03-24 |
| 2023-09-30 | $2.25M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $1.95M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $3.12M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $3.07M 10-K · filed 2024-04-01 |
| 2022-09-30 | $4.95M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $5.95M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $9.71M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $14.22M 10-K · filed 2023-03-15 |
| 2021-09-30 | $14.15M 10-Q · filed 2021-10-29 |
| 2021-06-30 | $18.54M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $17.87M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $17.00M 10-K · filed 2022-03-01 |
| 2020-09-30 | $16.41M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $13.69M 10-Q · filed 2020-08-14 |
| 2020-03-31 | $13.11M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $8.89M 10-K · filed 2021-03-01 |
| 2019-09-30 | $6.13M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $7.03M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $4.01M 10-Q · filed 2019-06-12 |
| 2018-12-31 | $1.46M 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |